Bronchiolitis obliterans is the leading cause of morbidity and mortality in the pulmonary transplant population with ≥50% of patients who receive a lung transplant developing the condition within 5 years.
The recommendation was supported by materials developed from the ALIS New Drug Application (NDA), which included data from the CONVERT study.
ALIS has previously been designated orphan drug status, breakthrough therapy status and a Qualified Infectious Disease Product.
For febrile infants, human rhinovirus is common, and detection does not alter risk of concomitant urinary tract infection or invasive bacterial infection.
A gas-capillary column ion mobility spectrometer may be a feasible and noninvasive tool for clinicians to diagnose respiratory tract infections in hospitalized patients.
A middle-aged man with no significant medical history presents to his local urgent care with flu-like symptoms but sees no improvement after starting antibiotics.
Clustering patients with interstitial lung disease independently predicted progression-free and transplant-free survival.
Patients who underwent open lung resections had a significantly higher incidence of postoperative pneumonia vs minimally invasive surgery.
Current and former smokers with COPD had much higher total airway mucin concentrations compared with patients who had never smoked.
Underlying cystic fibrosis may be a risk factor for the prediction of delayed gastric emptying in patients who undergo lung transplantation.
Advanced emphysema may benefit from endoscopic lung reduction treatment.
Respiratory infection frequency during the first 2 years of life is tied to celiac disease risk in high-risk children.
Increasing Vitamin D supplements does not prevent winter upper respiratory tract infections in young healthy children.